Wedam S, Narayan P, Gittleman H, Cheng J, et al. US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast J Clin Oncol 2025 Aug 22:JCO2500663. doi: 10.1200/JCO-25-00663.
PMID: 40845250